Dr James GarnerMA, MBA, MBBS, BSC (HONS)
Chief Executive Officer & Executive Director
Dr Garner is an experienced life sciences executive who has previously worked with companies ranging from small biotechs to multinational pharmaceutical companies such as Biogen and Takeda. His career has focused on regional and global development of new medicines from preclinical to commercialisation.
Dr Garner is a physician by training and holds an MBA from the University of Queensland. He began his career in hospital medicine and worked for a number of years as a corporate strategy consultant with Bain & Company before entering the pharmaceutical industry. Prior to joining Novogen in 2016, he led R&D strategy for Sanofi in Asia-Pacific and was based in Singapore.
Dr Andrew HeatonBSC, PHD
CEO & President, Novogen North America
Dr Heaton has 20 years drug design and discovery experience, having designed molecules in oncology, cardiovascular and anti-inflammatory, a number of which have successfully transitioned into clinical trials. He is the senior author on over 200 international patent applications. Dr Heaton was a co-founder of Triaxial Pharmaceuticals, which was acquired by Novogen in 2012, since then he has driven the discovery and early development of Novogen’s current pipeline of three molecules: Cantrixil, Anisina, and Trilexium. He previously worked with Novogen from 1999-2010, during which time he was responsible for translation of a number from drugs from the bench to the clinic, and also developed a series of innovative large-scale manufacturing programs. He has also developed a wide range of novel formulations for drug delivery, covering solid dose forms, sterile IV formulations, and innovative liposome formulations that facilitate drug delivery across the blood brain barrier.
Dr Heaton holds an adjunct Senior Lecturer position at UNSW School of Medicine, where he is creating novel molecular probes to aid the understanding of tropomyosin functionality. Dr Heaton gained his PhD in biologically active marine natural products from James Cook University and completed post-doctoral research in this area prior to entering industry.
Dr David BrownDIP TECH MGMT, B APP SC, PHD
Chief Scientific Officer
Dr David Brown joined Novogen in 2000 and championed the preclinical and translational development of the early Novogen compounds. In 2010, Dr Brown left Novogen and worked as a Medical Advisor for Janssen as part of the Regional Immunology group. Dr Brown is a co-founder of Triaxial Pharmaceuticals and as a result of Novogen’s acquisition of Triaxial, re-joined Novogen in 2013 as the company’s Group Chief Scientific Officer.
Dr Brown has over 20 years’ experience in all non-clinical aspect of drug discovery and development. He holds a PhD from the University of Queensland, has held several post-doctoral positions and has an Adjunct Senior Lecturer appointment with the UNSW. Dr Brown has authored 10 patents, several IND applications and over 30 peer-reviewed scientific articles.
Cristyn HumphreysBBUS (ACC), DIPPOL, FTI, CA
Chief Financial Officer
Ms Humphreys has 20 years commercial experience working for private industries including heading up finance, marketing and strategy departments for businesses with a global presence. Cristyn’s commercial experience is broad including founding a registered charity in Australia and working in the NSW Police Service. She is a Chartered Accountant and a Fellow of the Tax Institute in Australia.
Dr Peng LeongMBA, PHD
Chief Business Officer
Dr Leong has spent eighteen years in the pharmaceutical industry, beginning as a scientist, and followed by eight years in healthcare investment banking and private equity, and eight years in business development. Dr Leong started his career at Chiron Corporation, a pioneering biotechnology company based in California that was subsequently acquired by Novartis International AG (NYSE: NVS). While working in healthcare investment banking at CIBC World Markets and Piper Jaffray, he was involved in raising more than US$ 1.4 billion for over 20 biotechnology companies.
In his various roles, including his most recent position at Merck Serono (FWB: MRK), Dr Leong has had a leadership role in the acquisition or sale of over US$ 1 billion in pharmaceutical product rights. He holds a PhD in Biochemistry from the University of Toronto, Canada and an MBA from the University of California, Berkeley.
Dr Gordon HirschMBA, MBBCh, FCP(SA), BSc Hons
Chief Medical Officer
Dr Hirsch is a scientist, specialist physician and pharmaceutical executive with more than 20 years’ experience in the pharmaceutical industry. He has held various scientific, medical and operational roles at country, regional and global levels with a range of responsibilities from development to commercialisation in companies including Eli Lilly, Pfizer, Sanofi and Takeda. He has held appointments in South Africa, Australia, France, Japan and the United States.
He holds BSc Hons and MBBCh degrees from the University of the Witwatersrand, South Africa and an MBA from Henley Business School, UK. Dr Hirsch is also a Fellow of the South African College of Physicians.
Kate HillACA, GAICD, BSc (Hons)
Interim Company Secretary
Kate has over 20 years’ experience as an audit partner with Deloitte Touche Tohmatsu, working with ASX listed and privately owned clients. She has worked extensively in regulated environments including assisting with Initial Public Offerings, capital raising and general compliance, as well as operating in an audit environment. She is also a Non-executive Director of a small not-for-profit organisation and a member of their Finance and Risk Committee.
Kate is a member of the Institute of Chartered Accountants in Australia and New Zealand, and a graduate of the Australian Institute of Company Directors.